[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622718":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":77,"collaborators":31,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":31,"eligibilityCriteria":84,"healthyVolunteers":81,"sex":85,"minAge":86,"maxAge":31,"enrollmentInfo":87,"targetDuration":31,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":102,"overallStatus":50,"whyStopped":31,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Unity Health Toronto","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention arm - GA-Mainstream tool users","EXPERIMENTAL","Participants in the intervention arm will use the GA-Mainstream digital tool for cancer genetics education, providing cancer medical and family history, and to support the delivery of their genetic test results. This tool will be used to supplement usual care. Participants will continue to be supported by existing consultations with genetics professionals to discuss their results.",[13,14],"Behavioral: Genetics Adviser for Mainstream Care (GA-Mainstream)","Behavioral: Mainstreaming Standard of Care",{"label":16,"type":17,"description":18,"interventionNames":19},"Mainstreaming Standard of Care","ACTIVE_COMPARATOR","Participants in the control arm will receive mainstream care as outlined by the clinic where the patient is being seen, which consists of a patient pamphlet, video and\u002For a clinician checklist for pre-test counseling. Results will be disclosed by either a genetic counselor or oncologist with post-test counseling of select patients.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Genetics Adviser for Mainstream Care (GA-Mainstream)","The Genetics Adviser for Mainstream Care will educate participants on cancer genetic testing after oncologist-initiated genetic testing. Participants may also receive their results on the GA-Mainstream.",[9],[27],"GA-Mainstream",{"type":22,"name":16,"description":29,"armGroupLabels":30,"otherNames":31},"After oncologist-initiated genetic testing, participants may not receive additional information prior to the receipt of their results or they may receive educational materials on cancer genetic testing. Results will be disclosed by either a genetic counselor or oncologist with post-test counseling of select patients.",[9,16],null,[33],{"name":34,"affiliation":35,"role":36},"Yvonne Bombard, PhD","St. Michael's Hospital and University of Toronto","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Marc Clausen, MA","CONTACT","416-864-6060","77397","marc.clausen@unityhealth.to",{"name":45,"role":40,"phone":31,"phoneExt":31,"email":46},"Daniel Assamad, MHSc","d.abdassamad@mail.utoronto.ca",[48,67],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Sunnybrook Hospital","RECRUITING","Toronto","Ontario","M4N 3M5","Canada","CA",{"type":57,"coordinates":58},"Point",[59,60],-79.39864,43.70643,{"lat":60,"lon":59},[63,65],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":64},"Marc.Clausen@unityhealth.to",{"name":66,"role":36,"phone":31,"phoneExt":31,"email":31},"Andrea Eisen, MD",{"facility":68,"status":50,"city":51,"state":52,"zip":69,"country":54,"countryCode":55,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},"Mount Sinai Hospital","M5G 1X5",{"type":57,"coordinates":71},[59,60],{"lat":60,"lon":59},[74,75],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":64},{"name":76,"role":36,"phone":31,"phoneExt":31,"email":31},"Christine Elser, MD",{"type":78,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100622718","mainstreaming-genetics-evaluation-of-a-digital-application-to-scale-and-spread-oncologist-initiated-genetic-testing-100622718",false,"NCT07387263","Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing","Inclusion Criteria:\n\n* Receiving germline testing related to primary cancer condition initiated by oncologist\n* 18 years old or older.\n* Speak and read English\n\nExclusion Criteria:\n\n* Receiving cancer genetic testing via a referral to a genetics clinic\n* Do not speak or read English\n* Under 18 years of age\n* Determined to have diminished, marginal and or fluctuating decisional capacity\n* Lack access to internet or an electronic device","ALL","18 Years",{"count":88,"type":89},180,"ESTIMATED","INTERVENTIONAL",[92],"NA","Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon\u002FGI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.",[95,96,97,98,99,100,101],"Cancer","Breast Cancer","Prostate Cancer","Colon Cancer","GI Cancers","Ovarian Cancer","Pancreatic Cancer",[103,104,105,106,107,95,108,109,110],"Cancer Genetic Testing","Randomized Controlled Trial","Digital Tool","Mainstreaming","Genetic counseling","Genetic testing","Service Delivery","Alternative service delivery model","2026-06-19",{"date":113,"type":114},"2026-06-24","ACTUAL",{"date":116,"type":114},"2026-04-30",{"date":118,"type":89},"2027-03",{"name":5,"class":6},2]